Isomorphic Labs secures 5 billion dollars to accelerate AI drug discovery
Business & MoneyThe Neuron · 4d ago

Isomorphic Labs secures 5 billion dollars to accelerate AI drug discovery

Isomorphic Labs, an AI drug discovery company led by Demis Hassabis, has raised 5 billion dollars in Series C funding. Backed by investors including Alphabet and Sequoia, the firm plans to expand its computational molecule design system and build out its internal pipeline of experimental treatments.

Isomorphic LabsDemis HassabisAlphabetSequoiaGreenoaks

The Blend

Isomorphic Labs, a biotechnology venture led by Demis Hassabis and backed by Alphabet, has raised five billion dollars in its latest funding round. The investment was co-led by Sequoia Capital and Greenoaks, with participation from several major venture firms and sovereign funds. According to the company, this capital will be used to expand its computational drug design engine and advance its internal pipeline of experimental medical treatments.

Traditional drug discovery is an expensive and time-consuming process that often takes over a decade to yield results. By using artificial intelligence to analyze biological structures and predict chemical interactions, researchers aim to compress years of early-stage laboratory work into months. For average patients, this technology could eventually mean quicker access to new medications for difficult diseases and lower overall costs for novel treatments.

However, designing a promising candidate on a computer is only the initial hurdle. Algorithms can accurately model molecules, but those drugs must still undergo years of rigorous human clinical trials to prove they are safe and effective. It remains an open question whether AI designed compounds will actually beat the historically high failure rates of standard drug trials, or if they will simply help researchers reach those trial phases faster.

Written independently by AI News Smoothie from the reporting listed below. Facts belong to the original publishers. Follow the links for their full coverage.

Ingredients

Read the original